Jump to

In the article by Raval et al, “Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association,” which published ahead of print February 6, 2017, and appeared in the March 7, 2017, issue of the journal (Circulation. 2017;135:e604–e633. DOI: 10.1161/CIR.0000000000000477), several corrections were needed.

On page e609, in Table 2, for “Rivaroxaban,” in the second row, third column, the direction of the arrow has been changed to indicate an increase in exposure. The updated entry now reads, “↑ Rivaroxaban exposure.”

On page e613, in the right column, last paragraph, the second sentence read, “All NOACs except apixaban are contraindicated in patients on hemodialysis on the basis of their respective US prescribing monograph.” The sentence has been updated to read, “All NOACs should be used with caution in patients on hemodialysis, given the limited data available.”